Press Release

Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.

The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population

A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.

BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.

BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.

NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.